Fenofibrate, a PPAR-α agonist [8–12], bezafibrate, a panPPAR agonist [13–15], elafibranor, a dual PPAR-α and PPAR-δ agonist [16], saroglitazar, a dual PPAR-α and PPAR-γ agonist [17, 18], seladelpar (MBX-8025), a selective PPAR-δ agonist [19–21], have shown satisfying effect in decreasing markers of cholestasis and improving liver function in primary biliary cholangitis patients with incomplete UDCA response. This evidence concerns the gene PPARA and primary biliary cholangitis.